Many cancer drugs that are approved by the FDA do not have much benefit to patients. This is because approval can be based on dubious measurements of secondary benefits, referred to as “surrogate endpoints.” The FDA, with the help of Congress, has all but relinquished its role as a watchdog agency and instead treats Big Pharma as its partner. Changes that expedite drug approval are a gift to the pharmaceutical industry but expose patients to dangerous treatments that often deliver no benefit.
Write to the FDA, with a copy to Congress, urging the agency to stop the practice of approving cancer drugs on the basis of surrogate endpoints.
Stop the Use of Surrogate Endpoints for Cancer Drugs
Dear [Decision Maker],
Sincerely,[Your Name] [Your Address] [City, State ZIP][Your Email]